miR-155、EMT与肿瘤侵袭转移的研究进展

生物技术通报 ›› 2014, Vol. 0 ›› Issue (3): 55-59.

miR-155、EMT与肿瘤侵袭转移的研究进展

吴丽婷, 崔蕾, 王艳林, 黄利鸣

(三峡大学医学院分子生物学研究所，宜昌 443002)

收稿日期:2013-09-03 出版日期:2014-03-29 发布日期:2014-03-31
作者简介:吴丽婷，女，硕士研究生，研究方向:妇科肿瘤；E-mail:wlt644645757@foxmail.com
基金资助:
国家自然科学基金项目(30873282)，国家自然基金面上项目(81374024)湖北省自然科学基金重点项目(2009CDA060，2011CDB181)，湖北省卫生厅自然科学科基金项目(NX2011-9)

Research Progress on miR-155, EMT and Tumour Invasion/Metastasis

Wu Liting, Cui Lei, Wang Yanlin, Huang Liming

(Medical College，Institute of Molecular Biology，Three Gorges University，Yichang 443002)

Received:2013-09-03 Published:2014-03-29 Online:2014-03-31

摘要/Abstract

摘要： 肿瘤细胞发生上皮间质转化(EMT)是其获得侵袭和转移能力的关键环节之一，而miR-155是EMT的重要调节因子，它通过靶向调节参与这一过程的关键蛋白因子的表达而发挥作用。miR-155的上述功能具有组织和细胞特异性，即在不同的肿瘤组织细胞中它具有促进或抑制侵袭和转移的能力，其功能的发挥取决于其作用靶点的生物学特征。就miR-155与EMT以及肿瘤侵袭转移关系的研究进展作一综述。

关键词: miR-155, 上皮间质转化, 肿瘤, 侵袭, 转移

Abstract: EMT(epithelial-mesenchymal transition)is one of the key steps for tumor cells to obtain their ability of invasion and metastasis. miR-155 is an important regulator for EMT and effects EMT by targeting the key proteins involved in this process and inhibiting their expression. The function of miR-155 is tissue-and cell-specific, which can promote or inhibit tumor invasion/metastasis in different tumor tissues and cell types depending on the biological characteristics of the targeted protein moleculars. It reviewed the relationship among miR-155, EMT and tumor invasion/metastasis.

Key words: miR-155, EMT, Tumour, Invasion, Metastasis

吴丽婷, 崔蕾, 王艳林, 黄利鸣. miR-155、EMT与肿瘤侵袭转移的研究进展[J]. 生物技术通报, 2014, 0(3): 55-59.

Wu Liting, Cui Lei, Wang Yanlin, Huang Liming. Research Progress on miR-155, EMT and Tumour Invasion/Metastasis[J]. Biotechnology Bulletin, 2014, 0(3): 55-59.

参考文献

[1] Bartel DP. Micrornas:target recognition and regulatory functions[J]. Cell, 2009, 136(2):215-233.
[2] Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mamma-lian microRNA targets[J]. Cell, 2003, 115(7):787-798.
[3] Yu Z, Jian Z, Shen SH, et al. Global analysis of microRNA target gene expression reveals that miRNA targets are lower expressed in mature mouse and Drosophila tissues than in the embryos[J]. Nucleic Acids Res, 2007, 35(1):152-164.
[4] Denli AM, Tops BB, Plasterk RH, et al. Processing of primary micrornas by the microprocessor complex[J]. Nature, 2004, 432(7014):231-235.
[5] Diederichs S, Haber DA. Dual role for argonautes in microrna processing and posttranscriptional regulation of microrna expression[J]. Cell, 2007, 131(6):1097-1108.
[6] Rana TM. Illuminating the silence:understanding the structure and function of small RNAs[J]. Nat Rev Mol Cell Biol, 2007, 8(1):23-36.
[7] Weber MJ. New human and mouse microRNA genes found by homology search[J]. Febs, 2005, 272(1):59-73.
[8] Faraoni I, Antonetti FR, Cardone J, et al. mir-155 gene:a typical multifunctional microrna[J]. Biochim Biophys Acta, 2009, 1792(6):497-505.
[9] Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer[J]. Cancer Res, 2005, 65(15):7065-7070.
[10] Czyzyk-Krzeska MF, Zhang X. MiR-155 at the heart of oncogenic pathways[J]. Oncogene, 2013, doi:10. 1038/onc. 2013. 26(Epub ahead of print).
[11] Kong W, He L, Richards EJ, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer[J]. Oncogene, 2013, doi:10. 1038/onc. 2012. 636(Epub ahead of print).
[12] Yilmaz M, Christofori G:Mechanisms of motility in metastasizing cells[J]. Mol Cancer Res, 2010, 8:629-642.
[13] Ryu JK, Hong SM, Karikari CA, et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma[J]. Pancreatology, 2010, 10(1):66-73.
[14] Tili E, Michaille JJ, Wernickea D, et al. Mutator activity induced by microRNA-155(miR-155)links inflammation and cancer[J]. PNAS, 2011, 108(12):4908-4913.
[15] Sonkoly E, Janson P, Majuri ML, et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte- associated antigen 4[J]. J Allergy Clin Immu, 2010, 126(3):581-589.
[16] Moyal L, Barzilai A, Gorovitz B, et al. Mir-155 is involved in tumor progression of mycosis fungoides[J]. Experimental Dermatology, 2013, 22(6):431-433.
[17] Lamouille S, Subramanyam D, Blelloch R, et al. Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs[J]. Cell Biology, 2013, 25:1-8.
[18] Kong W, Yang H, He L, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA[J]. Mol Cell Biol, 2008, 28(22):6773-6784.
[19] Kong W, He L, Coppola M, et al. MicroRNA-155 regunates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer[J]. J Biol Chem, 2010, 285(23):17869-17879.
[20] Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development[J]. Proc Natl Acad Sci USA, 2007, 104(41):1617-16170.
[21] Yan XL, Jia YL, Chen L, et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression:Role of the S100A4-miR155-SOCS1-MMP9 axis[J]. Hepatology, 2013, 57(6):2274-2286.
[22] Li Z, Zhan W, Wang Z, et al. Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis[J]. Biochem Biophys Res Commun, 2006, 348(1):229-237.
[23] Lei C, Wang YL, Huang YR, et al. Up-regulated miR155 reverses the epithelial mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells[J]. PLoS One, 2012, 7(12):e52310.
[24] Xiang X, Zhuang X, Ju S, et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT[J]. Oncogene, 2011, 30:3440-3453.
[25] Sobrado VR, Moreno-Bueno G, Cubillo E, et al. The class I bHLH factors E2-2A and E2-2B regulate EMT[J]. Cell Sci, 2009, 122(7):1014-1024.